- Home
- NVGS vs KURA Comparison
NVGS vs KURA Comparison
Compare NVGS & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVGS
- KURA
- Stock Information
- Founded
- NVGS 1997
- KURA 2014
- Country
- NVGS United Kingdom
- KURA United States
- Employees
- NVGS N/A
- KURA N/A
- Industry
- NVGS Marine Transportation
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NVGS Consumer Discretionary
- KURA Health Care
- Exchange
- NVGS Nasdaq
- KURA Nasdaq
- Market Cap
- NVGS 1.2B
- KURA 1.5B
- IPO Year
- NVGS N/A
- KURA N/A
- Fundamental
- Price
- NVGS $16.02
- KURA $20.26
- Analyst Decision
- NVGS Strong Buy
- KURA Strong Buy
- Analyst Count
- NVGS 2
- KURA 6
- Target Price
- NVGS $21.00
- KURA $30.60
- AVG Volume (30 Days)
- NVGS 177.7K
- KURA 389.8K
- Earning Date
- NVGS 11-11-2024
- KURA 10-31-2024
- Dividend Yield
- NVGS 1.25%
- KURA N/A
- EPS Growth
- NVGS 48.43
- KURA N/A
- EPS
- NVGS 1.12
- KURA N/A
- Revenue
- NVGS $560,231,000.00
- KURA N/A
- Revenue This Year
- NVGS $2.78
- KURA N/A
- Revenue Next Year
- NVGS $2.16
- KURA N/A
- P/E Ratio
- NVGS $14.25
- KURA N/A
- Revenue Growth
- NVGS 11.73
- KURA N/A
- 52 Week Low
- NVGS $13.68
- KURA $7.41
- 52 Week High
- NVGS $18.18
- KURA $24.17
- Technical
- Relative Strength Index (RSI)
- NVGS 51.41
- KURA 51.74
- Support Level
- NVGS $14.92
- KURA $19.26
- Resistance Level
- NVGS $16.49
- KURA $21.36
- Average True Range (ATR)
- NVGS 0.43
- KURA 0.85
- MACD
- NVGS 0.03
- KURA 0.07
- Stochastic Oscillator
- NVGS 57.89
- KURA 46.55
About NVGS Navigator Holdings Ltd. (Marshall Islands)
Navigator Holdings Ltd owns and operates liquefied gas carriers, which include a fleet of handysize liquefied gas carriers. The company also owns a share in an ethylene export marine terminal at Morgan's Point, Texas on the Houston Ship Channel (the Ethylene Export Terminal) through a joint venture (the Export Terminal Joint Venture).
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.